SCHEMBL3099704

SCHEMBL3099704

CC1CCc2sc(NC(=O)c3ccccc3N3CCN(C(=O)OC(C)(C)C)CC3)nc2N1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.45
PTPN11 Q06124 1/20 0.43
GRAMD1A Q96CP6 1/20 0.40
TP53 P04637 3/20 0.40
THRB P10828 1/20 0.40
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
ATR Q13535 1/20 0.39
PARP1 P09874 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OGFRL1 Q5TC84 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL112005 0.79 GRAMD1A (0.53) BACE1PTPN11GRAMD1AMAPT
SCHEMBL109937 0.73 PTPN11 (0.66) BACE1PTPN11MAPTCKS1BSKP1
SCHEMBL21360304 0.71 BACE1 (0.54) BACE1PTPN11TP53THRBLMNA
SCHEMBL1134857 0.69 GPR119 (0.45) BACE1TP53THRBLMNAMAPT
SCHEMBL7352143 0.68 KMT2A (0.52) BACE1PTPN11TP53LMNAMAPT
SCHEMBL110679 0.68 GPR119 (0.54) BACE1PTPN11LMNAMAPTCKS1B
SCHEMBL2327346 0.68 GPR119 (0.51) BACE1PTPN11TP53THRBLMNA
SCHEMBL21157517 0.67 BACE1 (0.50) BACE1PTPN11THRBLMNACKS1B
SCHEMBL6159637 0.67 NPC1 (0.57) BACE1PTPN11TP53THRBLMNA
SCHEMBL26054717 0.67 GPR119 (0.50) BACE1PTPN11TP53THRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 BACE1 4207/4885PTPN11 789/4885GRAMD1A 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.